Contact Us
Our expert team at The Stay Young Center for Women is ready to help you achieve your dream body!
Diabetes, Obesity and Metabolism
De Block, C., Bailey, C. J., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2022). Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes, Obesity and Metabolism, 25(1), 3–17. https://doi.org/10.1111/dom.14831
Indian Journal of Endocrinology and Metabolism
Dutta, D., Surana, V., Singla, R., Aggarwal, S., & Sharma, M. (2021). Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian Journal of Endocrinology and Metabolism, 25(6), 475. https://doi.org/10.4103/ijem.ijem_423_21
Cardiovascular Diabetology
Fisman, E. Z., & Tenenbaum, A. (2021). The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovascular Diabetology, 20(1). https://doi.org/10.1186/s12933-021-01412-5
Frontiers in Endocrinology
Gallwitz, B. (2022). Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022. 1004044
Diabetes Care
Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020). Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care, 43(6), 1352–1355. https://doi.org/10.2337/dc19-1892
Diabetologia
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 65(8), 1251–1261. https://doi.org/10.1007/s00125-022-05715-4
Diabetes Therapy
Min, T., & Bain, S. C. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of Type 2 diabetes: the SURPASS Clinical Trials. Diabetes Therapy, 12(1), 143–157. https://doi.org/10.1007/s13300-020-00981-0
Cardiovascular Diabetology
Nauck, M. A., & D’Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1). https://doi.org/10.1186/s12933-022-01604-7
Endokrynologia Polska
Nowak, M., Nowak, W., & Grzeszczak, W. (2022). Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Endokrynologia Polska. https://journals.viamedica.pl/endokryn ologia_polska/article/download/EP.a 2022.0029/68429
The Journal of Clinical Endocrinology and Metabolism
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J. M., Duffin, K. L., Milicevic, Z., Haupt, A., & Robins, D. A. (2020). Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in Type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 106(2), 388–396. https://doi.org/10.1210/clinem/dgaa863
Drug Design Development and Therapy
Wang, L. (2022). Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. Drug Design Development and Therapy, Volume 16, 1547–1559. https://doi.org/10.2147/dddt.s358989
JCI Insight
Willard, F. S., Douros, J. D., Gabe, M., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., Van Der Velden, W. J. C., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D’Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17). https://doi.org/10.1172/jci.insight.140532
The New England Journal of Medicine
Jastreboff, A. M., Aronne, L. J., Ahmad, N., Wharton, S., Connery, L., Alves, B. E. S., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
Frontiers in Endocrinology
Gallwitz, B. (2022). Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022. 1004044
Journal of Education, Health and Sport
Stachyra, B., Wolanin, M., Stawikowski, C., Zielonka, B., Osińska, A., Wolanin, I., Madej, K., Dengler, B., Kowalczyk, I., & Krawiec, P. (2023). Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review. Journal of Education, Health and Sport, 18(1), 23–33. https://doi.org/10.12775/jehs.2023.18.01.003